Psilocybin derived compositions and methods using same
Described herein are formulations for treating, preventing, or ameliorating one or more of irritable bowel syndrome (IBS), rheumatoid arthritis (RA), fibromyalgia, post-traumatic stress disorder, PTSD, neuropathic pain, or symptoms associated with any of the foregoing. The formulations disclosed herein comprise a therapeutic dose of one more of psilocybin, psilocin, baeocystin, and norpsilocin. The formulations disclosed herein may also comprise one or more cannabinoids, such as cannabidiol (CBD), one or more psychobiotic compounds, such as Lactobacillus rhamnosus JB-1, one or more prebiotics, such as sorbitol or alginate, Hericium erinaceus or extract thereof, brain derived neurotrophic factor (BDNF), and a docosahexaenoic acid (DHA)-rich oil. Also described herein are methods utilizing the aforementioned compositions.
1 . An alkaloid composition comprising a first alkaloid compound selected from the group consisting of psilocybin and psilocin and a second alkaloid compound selected from the group consisting of baeocystin and norpsilocin, wherein an amount of the first alkaloid compound and an amount of the second alkaloid compound are present in a ratio ranging from about 1:3 to about 1:10 by weight, wherein the alkaloid composition is formulated as an oral formulation, wherein the oral formulation is in a form of a granule, a capsule, a pill, a caplet, a sachet, a gum, or a dissolvable oral strip.
2 . The alkaloid composition of claim 1 , wherein the first alkaloid compound is psilocybin.
3 . The alkaloid composition of claim 2 , wherein the second alkaloid compound is baeocystin.
4 . The alkaloid composition of claim 2 , wherein the second alkaloid is norpsilocin.
5 . The alkaloid composition of claim 1 , further comprising cannabidiol.
6 . The alkaloid composition of claim 1 , wherein the alkaloid composition further comprises one selected from the group consisting of an erinacines, hericenones, cyanthane terpenes, extracts from Hericium mushroom, and any combination thereof.
7 . The alkaloid composition of claim 1 , further comprising a psychobiotic.
8 . The alkaloid composition of claim 7 , wherein the psychobiotic is Lactobacillus rhamnosus.
9 . The alkaloid composition of claim 1 , further comprising a prebiotic.
10 . The alkaloid composition of claim 1 , further comprising one or more medicinal mushrooms or extracts thereof.
11 . The alkaloid composition of claim 1 , further comprising docosahexaenoic acid.